1. Metabolic Enzyme/Protease
  2. ATGL


Adipose triglyceride lipase (ATGL) is rate-limiting in the mobilization of fatty acids from cellular triglyceride stores. This central role in lipolysis marks ATGL as interesting pharmacological target since deregulated fatty acid metabolism is closely linked to dyslipidemic and metabolic disorders. Here we report on the development and characterization of a small-molecule inhibitor of ATGL. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo. ATGL performs the first step in triacylglycerol (TG) catabolism generating diacylglycerol which is subsequently degraded by hormone-sensitive lipase (HSL) and monoglyceride lipase (MGL) into glycerol and fatty acids (FA).

Adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) are the major enzymes contributing to triacylglycerol (TG) breakdown in in vitro assays and in organ cultures of murine white adipose tissue (WAT).

ATGL Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-15859
    Atglistatin Inhibitor
    Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
  • HY-148756
    NG-497 Inhibitor 98.67%
    NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL. NG-497 has potential value for tumor research[1].
  • HY-E70277
    Hexadecyl-CoA Inhibitor
    Hexadecyl-CoA is a thioether analog of acyl-CoA that can inhibit adipose triglyceride lipase (ATGL)[1].